<DOC>
	<DOCNO>NCT00441155</DOCNO>
	<brief_summary>To provide study drug patient benefit treatment judge investigator - obtain additional long-term safety efficacy data combination regimen GIST</brief_summary>
	<brief_title>Patients Completing Core Protocol ( CAMN107A2103 ) , Exhibiting Stable Disease ( SD ) , Partial Response ( PR ) Complete Response ( CR ) Nilotinib Combination With Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : Documented Complete Response , Partial Response , Stable Disease time entry extension study and/or possible benefit continue treatment view investigator . Normal organ marrow function define core protocol ( CAMN107A2103 ) . Extension protocol write informed consent . Exclusion criterion : Inability swallow medication . Any unresolved adverse event related participation core protocol ( CAMN107A2103 ) . A history noncompliance medical regimen inability unwillingness return schedule visit . Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Cancer</keyword>
	<keyword>Imatinib-Resistant Gastrointestinal Stromal Tumors</keyword>
	<keyword>GIST</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Imatinib-Resistant Gastrointestinal Stromal Tumors ( GIST )</keyword>
</DOC>